Bed Bath & Beyond Names Experienced Retail Merchant Stacey Shively As SVP, General Merchandise Manager To Enhance Position As Home Authority In The $180B Market

PR Newswire

UNION, N.J., May 13, 2021 /PRNewswire/ — Bed Bath & Beyond Inc. (Nasdaq: BBBY) has named Stacey Shively as Senior Vice President and General Merchandise Manager for Home effective May 17, 2021. Ms. Shively will report to Joe Hartsig, Bed Bath & Beyond’s Executive Vice President, Chief Merchandising Officer and President of Harmon Stores Inc. bolstering the Company’s leadership team to strengthen merchandising strategies across its home category.

Ms. Shively will be responsible for further accelerating merchandising plans for key categories including bed, bath, seasonal, décor, kitchen, dining, organization, electrics and general merchandise as part of the Company’s three-year transformation strategy. Facilitating cross-functional collaboration and full category management, Ms. Shively’s role will support the Company’s focus on the customer by elevating Bed Bath & Beyond in the marketplace with new products and experiences.

“As we continue to solidify Bed Bath & Beyond as the destination for home, we are focused on managing our merchandise assortment through a customer-inspired and omni-always lens,” CMO Hartsig said. “Stacey brings a wealth of knowledge and experience in retail with exceptional leadership skills delivering positive sales results in fast-paced, transformational environments. She is a powerhouse leader who I know will successfully manage the home business holistically.”

Ms. Shively joins Bed Bath & Beyond with more than 25 years of retail experience in merchandising, product development and inventory management. She has a proven track record in successfully managing assortment planning, product development and national and private-label brands while driving profitable sales. Most recently, Stacey served as the senior vice president, general merchandise manager for JCPenney’s home division where she was responsible for overseeing their merchandising strategies for home product categories. She began her career at Target where she held roles in merchandising and planning with increasing responsibility during her 17-year tenure. Ms. Shively also held leadership positions at Bluestem Brands and Dollar Tree.

“I am delighted to be joining Bed Bath & Beyond at such an exciting time for the Company. I have observed the early stages of the Company’s transformation and I am looking forward to lending my experience to support their plans, strengthening the merchandising approach for Home categories, and continuing to provide innovative strategies to support their growth objectives,” said Ms. Shively.

About Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc. and subsidiaries (the “Company”) is an omnichannel retailer that makes it easy for our customers to feel at home. The Company sells a wide assortment of merchandise in the Home, Baby, Beauty and Wellness markets. Additionally, the Company is a partner in a joint venture which operates retail stores in Mexico under the name Bed Bath & Beyond.

Bed Bath & Beyond operates websites at bedbathandbeyond.com, bedbathandbeyond.ca., buybuybaby.com, buybuybaby.ca, facevalues.com and decorist.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bed-bath–beyond-names-experienced-retail-merchant-stacey-shively-as-svp-general-merchandise-manager-to-enhance-position-as-home-authority-in-the-180b-market-301290854.html

SOURCE Bed Bath & Beyond Inc.

Wellteq Announces Strategic Partnership in Spain With Frontier Wellness Management / Apotheek Pharma Consulting

  • Wellteq (CSE.WTEQ) (OTC.WTEQF) signs letter of intent (LOI) detailing the general terms of a strategic partnership agreement with Frontier Wellness Management and its operating subsidiary Apotheek Pharma Consulting (FW-APC).
  • FW-APC are focused on marketing health and wellness solutions into their unique network of 140,000 medical professionals in the healthcare, pharmacy, and pharmaceutical markets in Spain.
  • Under the expected terms of a formal strategic partnership agreement, FW-APC will pay an initial EUR100,000 to Wellteq which will be expended on localization, further development, and integration. It is expected that Wellteq will be paid by each customer in accordance with their Software-as-a-Service (SaaS) user pricing.
  • Working with Wellteq’s sales and marketing personnel, FW-APC will immediately initiate marketing of the Wellteq application into FW-APC’s existing client list.
  • Wellteq will also be tasked with sourcing and integrating third-party applications under the strategic partnership.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

VANCOUVER, British Columbia, May 13, 2021 (GLOBE NEWSWIRE) — Wellteq Digital Health Inc.(CSE:WTEQ) (OTC:WTEQF), (the “Company” or “Wellteq”) is pleased to announce the Company has signed a letter of intent (the “LOI”) detailing the general terms of a strategic partnership with Frontier Wellness Management and its operating subsidiary Apotheek Pharma Consulting (FW-APC) in the European Union.

The FW-APC team have a combined 100 years of experience focused on marketing health and wellness solutions into their unique network of 140,000 medical professionals in the healthcare, pharmacy, and pharmaceutical markets in Spain.

Upon execution of a Formal Strategic Partnership Agreement, FW-APC will advance EUR100,000 to Wellteq. This amount will be applied toward application localization, development, and integration. Working with Wellteq sales and marketing personnel, FW-APC will immediately initiate marketing of the Wellteq smartphone application, working with Wellteq sales and marketing personnel, into FW-APC’s existing client base. FW-APC will ensure that white label solutions of Wellteq applications will be identified as “powered by Wellteq”.

Wellteq will be the technology partner for any required development of the Wellteq solution and for the sourcing and integration of third-party applications / solutions. Where ancillary revenues are generated through the deployed offerings, it is expected that the parties will agree on an equitable distribution of the revenue streams between FW-APC, Wellteq and any integrated third-party solution partners.

Wellteq is initiating European distribution ahead of schedule as part of its geographical expansion plans, reinforcing the market need for globally focused digital health platforms.

“The Spanish healthcare system is more acutely focused on prevention versus treatment when compared to most jurisdictions, and Wellteq fits perfectly within that system while also bringing significant economic benefit to those enterprises adopting the platform,” stated John MacPhail, CEO of Frontier Wellness.

“The pandemic has created a demand from our network of clients to improve and increase their digital presence not only for their customers but also for their employees. Wellteq provides a truly unique and universal solution to those needs,” said Carles Deulofeu, Managing Director of Apotheek Pharma Consulting.

Scott Montgomery, CEO of Wellteq, said, “Working with Frontier/Apotheek provides a unique and immediate marketing, sales and revenue opportunity for Wellteq’s digital health and wellness solutions and fast-tracks our entry into the European Union through a strategic partnership with an organization that has an incredibly deep relationship network already in place.”

About Frontier Wellness

Frontier Wellness Management is the parent company of Apotheek Pharma Consulting, a company focused on marketing health and wellness solutions into its unique network of 140,000 medical professionals in the healthcare, pharmacy, and pharmaceutical markets in Spain (ranked “Healthiest Country in the World” by Bloomberg in 2019). Apotheek, based in Barcelona, is works with strategic partners to secure, develop and market innovative and potentially industry disrupting health and wellness products and technologies into its vast network. The primary services of Apotheek include technology procurement, systems analysis, software integration, operational analysis, product integration, market research, regulatory affairs, marketing, and sales management.

About Wellteq Digital Health Inc.

Wellteq Digital Health Inc. is a leading provider of corporate wellness solutions developed to provide data-driven personalized health and wellness coaching to engage its users in healthier behaviours. As an enterprise (business-to-business) model, Wellteq currently has two main sectors of customers: employers and insurance companies. Wellteq has secured a large multinational portfolio of customers, including UBS, DBS and Bupa Insurance, and reseller partners, like Willis Towers Watson, Advanced Human Imaging and Garmin. Wellteq is developing its newly acquired Internet of Medical Things (IoMT) platform for virtual care applications which will extend the Wellteq continuum of care from preventative wellness through to virtual healthcare.

Investor Contact:         

Glen Akselrod
Bristol Investor Relations
E: [email protected]
T: (905) 326-1888

Sales & Partnership Contact:

[email protected]

Cautionary Note Regarding Forward-Looking Statements:

This news release contains information or statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Forward looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies and outlook of Wellteq, and includes statements about, among other things, future developments and the future operations, strengths and strategies of Wellteq. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.

The forward-looking statements made in this news release are based on management’s assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management’s experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analyses and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavourable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Wellteq’s products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.

The forward-looking information contained in this news release represents the expectations of Wellteq as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Wellteq undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

The CSE has neither approved nor disapproved the contents of this news release.



Dow leaders achieve top recognition on INvolve’s 2021 EMpower Ethnic Minority Role Model lists

Dow leaders achieve top recognition on INvolve’s 2021 EMpower Ethnic Minority Role Model lists

  • Five Dow leaders receive global recognition for helping ethnic minority employees break down barriers in the workplace

MIDLAND, Mich.–(BUSINESS WIRE)–
Dow (NYSE: DOW) today announced that five leaders earned recognition on three 2021 EMpower Ethnic Minority Role Model lists, including Top 20 Advocates, 100 Ethnic Minority Executives, and 100 Ethnic Minority Future Leaders.

The EMpower Ethnic Minority Role Model lists showcase business leaders who are breaking down barriers at work for ethnic minorities in the UK, Ireland, Europe, and people of color in the United States and Canada. Honorees are recognized for the success in their own careers and efforts to drive for more inclusive workplaces.

“Diversity in the workplace is a catalyst for business success,” said Karen S. Carter, chief human resources officer and chief inclusion officer. “At Dow, we are committed to diversifying our workforce across the talent pipeline and the global enterprise, which enables us to deliver the most value to our stakeholders.”

Dow employees selected for EMpower Ethnic Minority Role Model Lists include:

Top 20 Advocates List, #3

Jim Fitterling
, chairman and chief executive officer

Executive sponsor, Global African Affinity Network

Top 20 Ethnic Minority Executives List, #9

Mauro Gregorio
, president, Performance Materials & Coatings, Latin America oversight

Executive sponsor, Hispanic and Latin Network

Top 100 Ethnic Minority Executives List, #69

Karen S. Carter
, chief human resources officer and chief inclusion officer

Top 20 Ethnic Minority Future Leaders List, #13

Shruti Bahadur
, global program leader for eMarketplace, Customer and Employee Experience

North America leader, Asian Diversity Network

Top 100 Ethnic Minority Future Leaders List, #40

Kalyani Martinelango
, associate R&D director, Core R&D Engineering and Process Science

global chair, Asian Diversity Network

Last year, Dow announced the implementation of Dow ACTs, a strategic framework and action plan focusing on Advocacy, Community and Talent. The holistic plan demonstrates the Company’s commitment to address systemic racism in the U.S and accelerate change. As a strategic action, Dow has pledged $10 million over the next 5 years to help advance social justice and racial equality.

About Dow

Dow (NYSE: DOW) combines global breadth, asset integration and scale, focused innovation and leading business positions to achieve profitable growth. The Company’s ambition is to become the most innovative, customer centric, inclusive and sustainable materials science company, with a purpose to deliver a sustainable future for the world through our materials science expertise and collaboration with our partners. Dow’s portfolio of plastics, industrial intermediates, coatings and silicones businesses delivers a broad range of differentiated science-based products and solutions for its customers in high-growth market segments, such as packaging, infrastructure, mobility and consumer care. Dow operates 106 manufacturing sites in 31 countries and employs approximately 35,700 people. Dow delivered sales of approximately $39 billion in 2020. References to Dow or the Company mean Dow Inc. and its subsidiaries. For more information, please visit www.dow.com or follow @DowNewsroom on Twitter.

Ashley Mendoza

225-315-7132

[email protected]

KEYWORDS: United States North America Michigan

INDUSTRY KEYWORDS: Biotechnology Manufacturing Professional Services Health Other Science Natural Resources Other Manufacturing Engineering Science Human Resources Chemicals/Plastics

MEDIA:

Logo
Logo

Gabelli Dividend & Income Trust Continues Monthly Distributions, Declares Distributions of $0.11 Per Share

Gabelli Dividend & Income Trust Continues Monthly Distributions, Declares Distributions of $0.11 Per Share

RYE, N.Y.–(BUSINESS WIRE)–
The Board of Trustees of The Gabelli Dividend & Income Trust (NYSE:GDV) (the “Fund”) approved the continuation of its policy of paying fixed monthly cash distributions. The Board of Trustees declared cash distributions of $0.11 per share for each of July, August, and September 2021.

Distribution Month

Record Date

Payable Date

July

July 16, 2021

July 23, 2021

August

August 17, 2021

August 24, 2021

September

September 16, 2021

September 23, 2021

Additionally, the Board of Trustees continues to evaluate potential strategic opportunities for the Fund in what we believe to be an attractive environment to invest in the broader equity markets.

Each quarter, the Board of Trustees reviews the amount of any potential distribution from the income, realized capital gain, or capital available. The Board of Trustees will continue to monitor the Fund’s distribution level, taking into consideration the Fund’s net asset value and the financial market environment. If necessary, the Fund will pay an adjusting distribution in December which includes any additional income and net realized capital gains in excess of the monthly distributions for that year to satisfy the minimum distribution requirements of the Internal Revenue Code for regulated investment companies. The Fund’s distribution policy is subject to modification by the Board of Trustees at any time, and there can be no guarantee that the policy will continue. The distribution rate should not be considered the dividend yield or total return on an investment in the Fund.

All or part of the distribution may be treated as long-term capital gain or qualified dividend income (or a combination of both) for individuals, each subject to the maximum federal income tax rate for long term capital gains, which is currently 20% in taxable accounts for individuals (or less depending on an individual’s tax bracket). In addition, certain U.S. shareholders who are individuals, estates or trusts and whose income exceeds certain thresholds will be required to pay a 3.8% Medicare surcharge on their “net investment income”, which includes dividends received from the Fund and capital gains from the sale or other disposition of shares of the Fund.

If the Fund does not generate sufficient earnings (dividends and interest income, less expenses, and realized net capital gain) equal to or in excess of the aggregate distributions paid by the Fund in a given year, then the amount distributed in excess of the Fund’s earnings would be deemed a return of capital. Since this would be considered a return of a portion of a shareholder’s original investment, it is generally not taxable and would be treated as a reduction in the shareholder’s cost basis.

Long-term capital gains, qualified dividend income, investment company taxable income, and return of capital, if any, will be allocated on a pro-rata basis to all distributions to common shareholders for the year. Based on the accounting records of the Fund currently available, each of the distributions paid to common shareholders in 2021 would include approximately 14% from net investment income and 86% from net capital gains on a book basis. This does not represent information for tax reporting purposes. The estimated components of each distribution are updated and provided to shareholders of record in a notice accompanying the distribution and are available on our website (www.gabelli.com). The final determination of the sources of all distributions in 2021 will be made after year end and can vary from the monthly estimates. Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution. All individual shareholders with taxable accounts will receive written notification regarding the components and tax treatment for all 2021 distributions in early 2022 via Form 1099-DIV.

Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing. More information regarding the Fund’s distribution policy and other information about the Fund is available by calling 800-GABELLI (800-422-3554) or visiting www.gabelli.com.

About The Gabelli Dividend & Income Trust

The Gabelli Dividend & Income Trust is a diversified, closed-end management investment company with $2.9 billion in total net assets whose primary investment objective is to provide a high level of total return with an emphasis on dividends and income. The Fund is managed by Gabelli Funds, LLC, a subsidiary of GAMCO Investors, Inc. (NYSE:GBL).

NYSE – GDV

CUSIP – 36242H104

Investor Relations Contact:

Carter Austin

(914) 921-5475

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Radix IoT Announces New Management Promotions, Hires Expanding Its Global Footprint

Company Further Solidifies Its Market Leading Intuitive Unified IoT Platform Reach

DALLAS, May 13, 2021 (GLOBE NEWSWIRE) — Radix IoT–offering limitless monitoring and management rooted in intelligence–today announced the addition of several management promotions and hires to expand its global reach, and intellectual property portfolio.

“In less than two years, amidst a pandemic, our end-to-end IoT framework has become the most cohesive, efficient solution for data collection and aggregation, remote monitoring and process management–empowering critical facilities’ uninterrupted global operations,” said Fred Dirla, CEO of Radix IoT. “I look forward to leading our team of top expert executives and industry veterans to fortify and expand Radix IoT’s global footprint, with new product lines and entry into additional markets and verticals.”

As Vice President of Infrastructure,Kenneth Endfinger will focus on Radix IoT Cloud offering infrastructure, standards, and security, supporting Michael Skurla, Chief Product Officer, with intellectual property and M&A initiatives. He brings decades’ expertise in research, design, planning and building scalable, purpose-built IoT platforms. Previously as the company’s Research Director, Endfinger led a research team on emerging IoT technologies, and as Software Development Manager at BitBox USA developed the industry leading IoT Platform prior to the merger into Radix IoT. He is a former Software Engineer with Starrett-Bytewise Measurement Systems, Acuity Brands, and DGLogik.

As Global Vice President of Operations Dave Schaible will work closely with the company’s COO, Luke Dalske to expand the technical proficiency of BMS, SCADA and complex projects and develop a standard UI philosophy to fulfill Radix IoT’s vertical-specific client needs. With over 25 years’ experience in the BMS, SCADA and DCIM space as solution designer in the controls and monitoring field, focusing on data centers and mission critical facility applications, Schaible was previously Senior Director, and Director of Strategic Solutions at Nlyte Software and former Director of Operations at FieldView Solutions Inc.

Jason Thacker joins as Vice President of Engineering and quality assurance liaison to manage enterprise customer requirements, resource engineering development efforts, product release life-cycle testing program, and will execute best in class technical product management standards allowing the rapid growth of the Radix IoT Platform. He was previously Director of IT Programs and Project Management at TDOE, Director of Software Development at BitBox USA, and Director of Business Systems at Kirkland’s where he set the HR, Finance, and BI information system strategies including on premise, SaaS, and Cloud applications services.

Mads Volsted Pedersen will join the executive management team as Chief Technology Officer at Radix IoT, adding over five decades of combined expertise in programming, systems architecture, technical proficiency in BMS, SCADA and DCIM space. Pedersen will drive initiatives and efforts surrounding Mango platform development for the Radix IoT family of products. He brings deep technical development specialization and in-depth knowledge of managing a global team. Previous to Radix IoT, Pedersen managed software development at Forbes, 24/7 Real Media Inc. and EZSize.

Co-founder Michael Skurla will shift to the role of Chief Product Officer leading the global marketing and growth efforts, as well as product strategy focusing on intellectual property growth for Radix IoT markets, research initiatives, managed services, and M&A. Previously as CTO, Skurla guided the unification of acquired technology into the current award-winning Radix IoT portfolio. Skurla brings a wealth of market knowledge with over two decades of thought leadership in emerging building analytics and telemetry applications driven from analytics as well as IoT product design with Fortune 500 companies.

For more information, visit Radix IoT www.radixiot.com or contact [email protected].   
  
Radix IoT Resources  
Radix IoT Brochure
Radix IoT Products 
Radix IoT Markets 
Radix IoT Case Studies 
Radix IoT White Papers

About Radix IoT  
Radix IoT offers a flexible and unified IoT platform to unite and harness data from existing subsystems into a managed dashboard allowing remote monitoring, process management, and data aggregation intelligence to maximize uptime operations and minimize operating expenses. From one location to multiple, the Radix IoT portfolio of products solves the inherent complexity of managing geographically distributed facilities across various markets, including edge data centers, utilities, carrier edge/telecom infrastructure, industrial, and property management. Radix IoT is a wholly owned subsidiary of Compass Datacenters. It is headquartered in Dallas, TX, with offices in Mountain View (CA) and Chicago (IL). For more information, visit www.radixiot.com and Follow on Twitter, Facebook and LinkedIn.  

Media Contact:  
Jackie Abramian   
Global Cadence 
[email protected]    
617-584-2580   



Local Farmers Connect Backyard Gardeners to Soil Health with Launch of ReWild Garden Seed

A direct-from-farm blend of regenerative cover crops seeds to heal garden soil.

CRYSTAL CITY, Manitoba, May 13, 2021 (GLOBE NEWSWIRE) — Founded by a group of regenerative farmers and soil health advocates from Manitoba, ReWild Garden Seed is on a mission to connect gardeners with soil health. Owned by Covers & Co. agricultural seed company, ReWild Garden Seed officially launched in spring 2021, offering backyard farmers looking to improve the health of their soil an alternative to fertilizer.

“We like to say healthy soil, healthy garden, healthy people,” says Joseph Gardiner, co-founder of Covers & Co., and ReWild Garden Seed. “When we started regenerative farming on my family farm, we turned to cover cropping to replace our reliance on fertilizers, but it’s become more than that. It’s about restoring and respecting the balance of nature. We developed our Spring Fling Cover Crop blend as a way of recognizing that gardeners are farmers, too, and when we nurture our soil, we don’t just grow healthier, tastier food, we nurture our planet and each other, too.”

Spring Fling Cover Crop Blend

ReWild Garden Seed’s flagship garden blend, Spring Fling Cover Crop, contains a mix of annual grasses, broadleaves, and nitrogen-fixing legumes. It helps reduce weeds, and acting like green manure, can also eliminate fertilizer use by naturally adding organic matter into the soil. When Spring Fling is rotated annually through a garden, soil biology is stimulated, and the diversity of flowering plants is increased, offering valuable food for bees, butterflies, and other beneficial pollinators.

Spring Fling Cover Crop garden blend is now available at seven garden centres across Manitoba: Alternative Choice Garden Centre, Morden Nurseries, Pilot Mound Home Hardware, Schott Ranch Greenhouse and Market, The Green Spot Home and Garden, Vervain Greenhouse, and online and in-stores at T&T Seeds.

About ReWild Garden Seed:

ReWild Garden Seed connects backyard gardeners to soil health. Founded by Covers & Co. agricultural seed company, ReWild Garden Seed is owned and operated by regenerative farmers, soil health advocates, and hobby gardeners from the Canadian Prairies. Their flagship seed blend, Spring Fling Cover Crop, is designed to feed the soil—restoring nutrients, reducing weeds, and eliminating the use of fertilizers—for a healthier garden. The Spring Fling Cover Crop blend contains 15 diverse plant species, including annual grasses, broadleaves, and nitrogen-fixing legumes. Learn more about how ReWild Garden Seed is bringing garden soil back to life: rewildgardenseed.com

Media Contact: Kennedy Collins, [email protected], (204) 208-0122 Patricia Benton, [email protected], (778) 828-3990
Instagram/Facebook @rewildgardenseed
Website: rewildgardenseed.com
Images: download link



Husson University Honored Retirees During Eighth Annual Tree Planting Ceremony

Two blue spruce trees were planted on Husson University’s campus in recognition of this year’s six retirees.

BANGOR, MAINE, May 13, 2021 (GLOBE NEWSWIRE) — Husson University honored recent retirees with a tree planting ceremony on Wednesday, May 12, 2021 at 2 p.m. on its Bangor campus. Two trees were planted in recognition of six individuals whose efforts helped make this remarkable institution of higher learning a success.

Husson University employees honored included (in alphabetical order):

  • Priscilla Bisher, MS, RN-BC, an instructor in the School of Nursing
  • Patricia Bixel, PhD, dean of the College of Science and Humanities
  • Janice Clark, an administrative coordinator for Athletics.
  • Laurie Eddy, MSN, RN, FNP – BC, WHCNP, an assistant professor at the Wellness Center
  • Mary Ann Haas, the chief of staff in the Office of the President
  • Rhonda Waskiewicz, EdD, OT, dean of the College of Health and Pharmacy

“Each year, this ceremony honors the dedicated individuals who have helped our students grow and achieve success in a variety of professional careers. It’s an honor to plant these trees and commemorate their contributions to our University,” said Senior Vice President for Academic Affairs and Provost Dr. Lynne Coy-Ogan.

Celebrants gathered in between the lampposts that border the newly made access road that leads to the Peabody service area, on the Boucher Field side of the road. The new access road is the same one that leads to the Peabody Hall loading dock and the parking area for Husson University Safety and Security vehicles.

Two blue spruce trees were planted along the west side of the access road in recognition of this year’s six retirees. In past years, the University has planted flowering crabapple trees.

Last year’s tree planting ceremony was recorded and celebrated as a virtual event due to the pandemic. Husson University was looking forward to resuming an in-person employee celebration this year. Participants observed all masking and physical distancing protocols established by the state and federal Centers for Disease Control and Prevention (CDC).

For more than 120 years, Husson University has shown its adaptability and strength in delivering educational programs that prepare future leaders to handle the challenges of tomorrow through innovative undergraduate and graduate degrees. With a commitment to delivering affordable classroom, online and experiential learning opportunities, Husson University has come to represent a superior value in higher education. The hallmarks of a Husson education include advanced knowledge delivered through quality educational programs. According to a recent analysis of tuition and fees by U.S. News & World Report, Husson University is one of the most affordable private colleges in New England. For more information about educational opportunities that can lead to personal and professional success, visit Husson.edu.

Attachments



Eric B. Gordon
Husson University
207.649.4647
[email protected]

Flux Power Announces Record Quarterly Revenue of $7.0M for Third Quarter of FY 2021; Increase of 38% YOY

Flux Power Announces Record Quarterly Revenue of $7.0M for Third Quarter of FY 2021; Increase of 38% YOY

Investor Conference Call at 4:30 PM ET

VISTA, Calif.–(BUSINESS WIRE)–
Flux Power Holdings, Inc. (NASDAQ: FLUX), a developer of advanced lithium-ion industrial batteries for commercial and industrial equipment, today reported financial results for its third quarter of fiscal year 2021 (Q3’21).

Financial Highlights:

  • Q3’21 revenue grew 38% to a record $7.0M compared to Q3’20 revenue of $5.1M.
  • Q3’21 gross margin increased to 24.1% compared to 12.8% in Q3’20.

Strategic Highlights:

  • Achieved 11th consecutive quarter of year-over-year revenue growth.
  • Received initial orders for two major new customers – a global packaging company and a paper & chemicals manufacturer/distributor.
  • Continued progress on increasing gross margins.
  • Launched the next-generation M24 lithium-ion battery pack for end riders and center riders, at the ProMatDX material handling tradeshow, with initial orders already received.

Q3’21 Financial Results

Revenue: Q3’21 revenue increased by 38% to $7.0M compared to $5.1M in Q3’20, driven by increases in sales of larger capacity product lines.

Gross Profit: Q3’21 gross profit improved by 158% to $1.7M compared to a gross profit of $649K in Q3’20, principally reflecting higher revenue and reduced material costs through volume purchasing.

Selling & Administrative: Expenses increased to $3.1M in Q3’21 from $2.6M in Q3’20, reflecting increases in personnel related expenses, insurance premiums, and freight expenses.

Research & Development: Expenses remained constant at $1.5M in Q3’21, compared to Q3’20, reflecting continued product development activities and product testing.

Net Loss: Q3’21 net loss decreased to $1.7M from a net loss of $4.0M in Q3’20, principally reflecting increased gross profit, other income due to PPP loan forgiveness, and decreased interest expense.

Balance Sheet: The balance sheet was strengthened during Q3’21 from conversion of all outstanding short-term debt of $2.4M during the quarter, resulting in the elimination of all debt. Further, $1.7M was raised under the ATM (At-the-Market) facility during Q3’21.

Fiscal Year 2021 Outlook

We anticipate that new customer acquisition will continue, supplementing continued orders from existing customers, with additional opportunities facilitated by the next-generation M24 lithium-ion battery pack for the high-volume end rider segment. The airport ground support equipment business is experiencing a resurgence following the COVID-19 impact.

We believe Flux Power is in a strong place to continue expansion to meet the demand for lithium-ion battery packs. However, supply chain challenges, both for semi-conductors, raw materials, and generic issues in ocean freight, present a risk to this growth, despite mitigation plans in place.

“We are excited by the initial customer reception of our next-generation M24 lithium-ion battery pack for the end rider and center rider market, which is a high-volume forklift sector,” CEO Ron Dutt stated. “We believe it’s a great addition to our full product lineup which provides a high value proposition to our customers with large material handling fleets.”

Conference Call

Management will hold a conference call today starting at 4:30 PM ET. Investors and analysts interested in joining the call are invited to dial (833) 428-8374 or (270) 240-0543. The conference ID is 7359227. A recording of the conference call will be uploaded to the Flux Power website once it is available.

About Flux Power Holdings, Inc. (www.fluxpower.com)

Flux Power designs, develops, manufactures, and sells advanced lithium-ion energy storage solutions for lift trucks, airport ground support equipment (GSE), stationary energy storage, and other industrial and commercial applications. Flux Power’s “LiFT Pack” battery packs, including its proprietary battery management system (BMS), provide its customers with a better performing, higher value, and more environmentally friendly alternative as compared to traditional lead acid and propane-based solutions.

Cautionary Statement Regarding Forward-Looking Statements

This release contains projections and other “forward-looking statements” relating to Flux Power’s business, that are often identified using “believes,” “expects” or similar expressions. Forward-looking statements involve several estimates, assumptions, risks, and other uncertainties that may cause actual results to be materially different from those anticipated, believed, estimated, expected, etc. Such forward-looking statements include impact of COVID-19 on Flux Power’s business, results and financial condition; Flux Power’s ability to obtain raw materials and other supplies for its products at competitive prices and on a timely basis, particularly in light of the potential impact of the COVID-19 pandemic on its suppliers and supply chain; the development and success of new products, projected sales, Flux Power’s ability to timely obtain UL Listing for its products, Flux Power’s ability to fund its operations, distribution partnerships and business opportunities and the uncertainties of customer acceptance and purchase of current and new products. Actual results could differ from those projected due to numerous factors and uncertainties. Although Flux Power believes that the expectations, opinions, projections, and comments reflected in these forward-looking statements are reasonable, they can give no assurance that such statements will prove to be correct, and that the Flux Power’s actual results of ‎operations, financial condition and performance will not differ materially from the ‎results of operations, financial condition and performance reflected or implied by these forward-‎looking statements. Undue reliance should not be placed on the forward-looking statements and Investors should refer to the risk factors outlined in our Form 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov/edgar.These forward-looking statements are made as of the date of this news release, and Flux Power assumes no obligation to update these statements or the reasons why actual results could differ from those projected.

Flux, Flux Power, and associated logos are trademarks of Flux Power Holdings, Inc. All other third-party brands, products, trademarks, or registered marks are the property of and used to identify the products or services of their respective owners.

Follow us at:

Blog: Flux Power Blog

News Flux Power News

Twitter: @FLUXpwr

LinkedIn: Flux Power

FLUX POWER HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

 

 

March 31, 2021

(Unaudited)

 

 

June 30,

2020

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash

 

$

2,432,000

 

 

$

726,000

 

Accounts receivable

 

 

4,864,000

 

 

 

3,069,000

 

Inventories

 

 

8,611,000

 

 

 

5,256,000

 

Other current assets

 

 

780,000

 

 

 

787,000

 

Total current assets

 

 

16,687,000

 

 

 

9,838,000

 

Right of use asset

 

 

3,138,000

 

 

 

3,435,000

 

Other assets

 

 

132,000

 

 

 

174,000

 

Property, plant and equipment, net

 

 

1,044,000

 

 

 

528,000

 

 

 

 

 

 

 

 

 

 

Total assets

 

$

21,001,000

 

 

$

13,975,000

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

6,050,000

 

 

$

4,648,000

 

Accrued expenses

 

 

1,750,000

 

 

 

1,400,000

 

Deferred revenue

 

 

115,000

 

 

 

4,000

 

Customer deposits

 

 

155,000

 

 

 

1,563,000

 

Due to Factor

 

 

 

 

 

469,000

 

Short-term loans – related party

 

 

 

 

 

2,057,000

 

Line of credit – related party

 

 

 

 

 

5,290,000

 

Financing lease payable

 

 

 

 

 

28,000

 

Office lease payable, current portion

 

 

419,000

 

 

 

288,000

 

Accrued interest

 

 

3,000

 

 

 

50,000

 

Total current liabilities

 

 

8,492,000

 

 

 

15,797,000

 

 

 

 

 

 

 

 

 

 

Long term liabilities:

 

 

 

 

 

 

 

 

Paycheck Protection Program loan payable

 

 

 

 

 

1,297,000

 

Office lease payable, less current portion

 

 

2,979,000

 

 

 

3,301,000

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

 

11,471,000

 

 

 

20,395,000

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity (deficit):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value; 500,000 shares authorized; none issued and outstanding

 

 

 

 

 

 

Common stock, $0.001 par value; 30,000,000 shares authorized; 13,003,795 and 7,420,487 shares issued and outstanding at March 31, 2021 and June 30, 2020, respectively

 

 

13,000

 

 

 

7,000

 

Additional paid-in capital

 

 

72,002,000

 

 

 

46,985,000

 

Accumulated deficit

 

 

(62,485,000

)

 

 

(53,412,000

)

 

 

 

 

 

 

 

 

 

Total stockholders’ equity (deficit)

 

 

9,530,000

 

 

 

(6,420,000

)

 

 

 

 

 

 

 

 

 

Total liabilities and stockholders’ equity (deficit)

$

21,001,000

$

13,975,000

 

 

FLUX POWER HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

 

Three Months Ended

March 31,

 

 

Nine Months Ended

March 31,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Revenues

 

$

6,964,000

 

 

$

5,051,000

 

 

$

17,932,000

 

 

$

10,585,000

 

Cost of sales

 

 

5,287,000

 

 

 

4,402,000

 

 

 

13,893,000

 

 

 

9,494,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

1,677,000

 

 

 

649,000

 

 

 

4,039,000

 

 

 

1,091,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling and administrative expenses

 

 

3,122,000

 

 

 

2,584,000

 

 

 

9,177,000

 

 

 

7,075,000

 

Research and development

 

 

1,523,000

 

 

 

1,527,000

 

 

 

4,624,000

 

 

 

3,888,000

 

Total operating expenses

 

 

4,645,000

 

 

 

4,111,000

 

 

 

13,801,000

 

 

 

10,963,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating loss

 

 

(2,968,000

)

 

 

(3,462,000

)

 

 

(9,762,000

)

 

 

(9,872,000

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income

 

 

1,307,000

 

 

 

 

 

 

1,307,000

 

 

 

 

Interest expense

 

 

(64,000

)

 

 

(503,000

)

 

 

(618,000

)

 

 

(1,214,000

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(1,725,000

)

 

$

(3,965,000

)

 

$

(9,073,000

)

 

$

(11,086,000

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share – basic and diluted

 

$

(0.14

)

 

$

(0.78

)

 

$

(0.80

)

 

$

(2.17

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding – basic and diluted

 

 

12,499,870

 

 

 

5,107,845

 

 

 

11,300,229

 

 

 

5,105,982

 

 

Media & Investor Relations:

Justin Forbes

877-505-3589

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Hardware Automotive Manufacturing Alternative Energy Aerospace Energy Manufacturing Technology Other Transport Trucking Air Transport Other Technology Other Manufacturing Other Energy Public Transport

MEDIA:

Logo
Logo

The Q Onboards New Ad Partner: Britannia

PR Newswire

  129 Year Old Iconic India Food Brand Available In Five Million Retail Outlets Across India

MUMBAI and TORONTO, May 13, 2021 /PRNewswire/ – QYOU Media Inc. (TSXV:QYOU) (OTCQB: QYOUF) has announced that The Q India, the company’s Hindi language youth oriented channel available in over 100 million TV households and to over 612 million  OTT and mobile users in India, has reported the addition of Britannia as a new advertiser on the rapidly growing channel.  The Britannia Brand is regularly listed as among the most trusted, valuable and popular brands across India and represents the addition of yet another prestigious name to the growing list of Fast Moving Consumer Goods (FMCG) companies selecting The Q India as a channel partner to reach Young India consumers.  Britannia joins a list of recently added advertisers including Pepsi, Unilever, Amazon and Wipro.

Britannia was founded in 1892 and is publicly traded on both the BSE (Bombay Stock Exchange) and NSE (National Stock Exchange) where it is listed on the Nifty 50, a benchmark India stock market index representing the weighted average of 50 of the largest Indian companies listed on the exchange.  The company has long held the distinction of being the largest seller of biscuits in the country and sells nearly one million loaves of bread daily across more than 100 cities and towns in India. 

Curt Marvis, QYOU Media CEO and Co-Founder added, “We continue to build the list of leading global and India based brands who are choosing The Q India as a key marketing and channel partner where they can place their products and services in front of our growing Young India audience.  It feels like every week we are bringing onboard new premium advertisers who are excited to align with the fastest growing channel in all of India and support our mission to attract young and savvy digital consumers.  We often speak about this process being a marathon…not a sprint…but the speed with which we are being recognized and sought after by leading brands is certainly gratifying and always grows our confidence in our stated mission to drive strong revenue growth in 2021 and beyond.

The Q India is an advertiser and influencer marketing supported Hindi language content brand, channel and VOD provider delivering hit digital programming from social media stars and leading digital video creators targeting Young Indian audiences.  The channel has recently become one of India’s fastest growing youth entertainment brands reaching a peak of 49.06 Gross Rating Points (GRP) on BARC (Broadcast Audience Research Council) in April 2021. With a growing library of over 1000 programs, and beginning in April with the addition of DD Free Dish, the channel reaches an audience of over 712 million via 100 million television homes with partners including DD Free Dish, TATA Sky, DISH TV and SitiNetworks; 380 million OTT users via platforms including ShemarooMe, MX Player, ZEE5, and Dish Watcho; and 232 million users on mobile and digital platforms including Snap, JioTV, Airtel Xstream, Amazon Fire TV, Chingari and Samsung TV Plus.


About QYOU Media.

QYOU Media operates in India and the United States producing and distributing content created by social media stars and digital content creators. In India, we curate, produce and distribute premium content including television networks and VOD for cable and satellite television, OTT and mobile platforms. In the United States, we manage influencer marketing campaigns for major film studios and brands. Founded and created by industry veterans from Lionsgate, MTV, Disney and Sony, QYOU Media’s millennial and Gen Z-focused content reaches more than 710 million consumers around the world.  Experience our work at www.qyoumedia.com and www.theq.tv

Join our shareholder chat group on Telegram:  http://t.me/QYOUMedia

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/the-q-onboards-new-ad-partner-britannia-301290834.html

SOURCE QYOU Media Inc.

Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency


Safety and efficacy
study
for
macimorelin
initiated
as agreed with
U
.
S
.
FDA and
the European Medicines Agency (“EMA”) in the Company’s Pediatric Investigation Plan (“PIP”)

– Patient enrollment on track
to start
this quarter

– Planned completion of
pivotal Phase 3 study
expected in
Q3 2022

CHARLESTON, S.C., May 13, 2021 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced the commencement of its pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“the DETECT-trial”) evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency (“CGHD”).

The investigational new drug application (“IND”), “Multicenter, open-label trial to investigate the efficacy and safety of a single oral dose of 1.0 mg/kg macimorelin acetate as growth hormone stimulation test (“GHST”) in pediatric patients with suspected growth hormone deficiency (“GHD”),” for the study is active and the first clinical site in the U.S. is open for patient recruitment.

Children and adolescents from two to less than 18 years of age with suspected growth hormone deficiency are planned to be included. The study is expected to enroll approximately 100 participants worldwide, with at least 40 participants in pre-pubertal and 40 participants in pubertal status. A macimorelin GHST will be performed twice to ensure the repeatability of the data. Two standard GHSTs will be used as controls: arginine (i.v.) and clonidine (p.o.). The study design is expected to be suitable to support a claim for potential stand-alone testing with macimorelin, if successful.

“The initiation of the pivotal Phase 3 DETECT-trial is a key milestone for the Company,” commented Dr. Klaus Paulini, Chief Executive Officer of Aeterna. “While we continue to make progress on multiple fronts across our development pipeline, the launch of this pivotal trial for the diagnosis of CGHD remains an integral piece of our product portfolio and an area of key focus. As sponsors of the trial, we look forward to getting the remainder of the clinical sites active and patient enrollment underway as quickly and efficiently as possible.”

The Company announced positive results in April 2020 from AEZS-130-P01 (“Study P01”), the first of two studies as agreed with FDA and EMA. The goal of Study P01 was to establish a dose that could both be safely administered to pediatric participants and causes a clear rise in growth hormone concentration in participants ultimately diagnosed as not having GHD. Results from the study demonstrated that the pharmacokinetic and pharmacodynamic profile of macimorelin proved to be in the expected range and in general comparable to data in adults.

Under new terms and conditions of the license agreement revised in November 2020, Aeterna is closely coordinating the activities related to the development of macimorelin in CGHD through a joint steering committee with Novo Nordisk, Aeterna’s licensee for the U.S. and Canada.

For more information about Study P01 and the DETECT-trial, please visit EU Clinical Trials Register and reference EudraCT #2018-001988-23 and clinicaltrials.gov identifier NCT04786873.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company’s lead product, macimorelin (Macrilen), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD) in collaboration with Novo Nordisk.

Aeterna Zentaris is dedicated to the development of therapeutic assets and has recently taken steps to establish a growing preclinical pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), hypoparathyroidism and an undisclosed neurodegenerative disease. Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2, the virus that causes COVID-19.

For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains statements that may constitute forward-looking statements within the meaning of U.S. and Canadian securities legislation and regulations, and such statements are made pursuant to the safe-harbor provision of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements are frequently, but not always, identified by words such as “expects,” “anticipates,” “believes,” “intends,” “potential,” “possible,” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties, and assumptions, known and unknown, many of which are beyond our control. Forward-looking statements in this press release include, but are not limited to, those relating to: Aeterna’s expectation with respect to Study P02 (including the ability to initiate the remainder of the clinical sites, to enroll subjects in the USA or elsewhere in Study P02, and expectations that Study P02 are suitable to support a claim (regulatory approval) for potential stand-alone testing with macimorelin), and Aeterna’s intentions with respect to growth opportunities and its business focus, including its development pipeline.

Forward-looking statements involve known and unknown risks and uncertainties, and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks and uncertainties include, among others, our reliance on the success of the pediatric clinical trial in the European Union and U.S. for Macrilen (macimorelin); we may be unable to enroll the expected number of subjects in Study P02 and the result of Study P02 may not support receipt of regulatory approval in CGHD, we may be delayed or unsuccessful in obtaining pricing and reimbursement approvals in Europe and the UK to market macimorelin; our other products under development may not be successful or may not support advancing the product to human clinical trials; our ability to raise capital and obtain financing to continue our currently planned operations; our now heavy dependence on the success of Macrilen (macimorelin) and related out-licensing arrangements and the continued availability of funds and resources to successfully commercialize the product, including our heavy reliance on the success of the License Agreement with Novo Nordisk; the global instability due to the global pandemic of COVID-19, and its unknown potential effect on our planned operations; our ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect. Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties, including those risks discussed in our Annual Report on Form 40-F and annual information form, under the caption “Risk Factors”. Given the uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this release.

Investor Contact:

Jenene Thomas
JTC Team
T (US): +1 (833) 475-8247
E: [email protected]